Actrapid® FlexPen® 100 IUml Solution for Injection in Pre-filled Pen

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
31-07-2021
Ciri produk Ciri produk (SPC)
31-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
07-07-2021

Bahan aktif:

Insulin human

Boleh didapati daripada:

NOVO NORDISK PHARMA (MALAYSIA) SDN. BHD.

INN (Nama Antarabangsa):

Insulin human

Unit dalam pakej:

3ml x 5 Units

Dikeluarkan oleh:

Novo Nordisk Production SAS

Risalah maklumat

                                ACTRAPID
®
100 IU/ml
Solution for injection
Pre-filled pen, FlexPen
®
Insulin human (rDNA)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
_ _
WHAT IS IN THIS LEAFLET
1.
What Actrapid
®
is used for
2.
How Actrapid
®
works
3.
Before you use Actrapid
®
4.
How to use Actrapid
®
5.
While you are using it
6.
Side effects
7.
Storage and disposal of
Actrapid
®
8.
Product description
9.
Manufacturer
10.
Product Registration Holder
11.
Date of revision
1. WHAT ACTRAPID
® IS USED FOR
ACTRAPID
®
IS HUMAN INSULIN USED TO
TREAT DIABETES.
Diabetes mellitus is a
disease
where
your
body
does
not
produce enough insulin to control the
level of your blood sugar.
2. HOW ACTRAPID
® WORKS
Actrapid
®
is a fast-acting insulin. This
means that it will start to lower your
blood sugar about ½ hour after you
take it, and the effect will last for
approximately 8 hours. Actrapid
®
is
often
given
in
combination
with
longer-acting insulin products.
3. BEFORE YOU USE ACTRAPID
®
_- WHEN YOU MUST NOT USE IT _
_ _
►IN INSULIN INFUSION PUMPS.
►IF
YOU
ARE
ALLERGIC
(HYPERSENSITIVE)
to human insulin or
any
of
the
other
ingredients
in
Actrapid
®
(see section 8.
_Product _
_description_
).
►IF
YOU
SUSPECT
HYPOGLYCAEMIA
(low blood sugar) is starting (see
section 4.
_How to use Actrapid_
_®_
).
►
IF
THE
FLEXPEN
®
IS
DROPPED,
DAMAGED OR CRUSHED.
►
IF IT HAS NOT BEEN STORED CORRECTLY
or
been
frozen
(see
section
7.
_Storage and Disposal of Actrapid_
_®_
).
►
IF
THE
INSULIN
DOES
NOT
APPEAR
CLEAR AND COLOURLESS.
_- BEFORE YOU START TO USE IT _
►
CHECK THE LABEL TO MAKE SURE
it is
the right type of insulin.
►
ALWAYS USE A NEW NEEDLE
for each
injection to prevent contamination.
►NEEDLES AND ACTRAPID
®
FLEXPEN
®
MUST NOT BE SHARED.
_- TAKING OTHER MEDICINES_
Some
medicines
affect
the
way
glucose works in your body and this
may
influence
your
insulin
dose.
Listed below are the most common
medicines
which
may
affect
your
insulin
treatment.
Tell
your
doctor,
nurse or pharmacist if you are taking or
have
recently
taken
any
oth
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                Actrapid
®
FlexPen
®
Professional leaflet_EN-May-2021_site France_8-XXXX-XX-XXX-X
Based on EU text: 20200603_EN_06946_APID_30-2
1
ACTRAPID
®
FlexPen
®
100 IU/ml
Solution for injection in pre-filled pen.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Insulin human, rDNA (produced by recombinant DNA technology in
_Saccharomyces cerevisiae_
).
1 ml contains 100 IU of insulin human.
1 pre-filled pen contains 3 ml equivalent to 300 IU.
One IU (International Unit) corresponds to 0.035 mg of anhydrous human
insulin.
PHARMACEUTICAL FORM
Solution for injection in pre-filled pen.
Clear, colourless, aqueous solution.
THERAPEUTIC INDICATIONS
Treatment of diabetes mellitus.
POSOLOGY AND METHOD OF ADMINISTRATION
Actrapid
®
is a fast-acting insulin and may be used in combination with
long-acting insulin products.
DOSAGE
Dosage is individual and determined in accordance with the needs of
the patient. The individual insulin
requirement is usually between 0.3 and 1.0 IU/kg/day. The daily
insulin requirement may be higher in
patients with insulin resistance (e.g. during puberty or due to
obesity) and lower in patients with residual,
endogenous insulin production.
An injection should be followed within 30 minutes by a meal or snack
containing carbohydrates.
DOSAGE ADJUSTMENT
Concomitant illness, especially infections and feverish conditions,
usually increases the patient’s insulin
requirement. Concomitant diseases in the kidney, liver or affecting
the adrenal, pituitary or thyroid gland can
require changes in the insulin dose. Adjustment of dosage may also be
necessary if patients change physical
activity or their usual diet. Dosage adjustment may be necessary when
transferring patients from one insulin
preparation to another.
ADMINISTRATION
For subcutaneous or intravenous use.
Actrapid
®
is administered subcutaneously by injection in the abdominal wall. If
convenient, the thigh, the
gluteal region or the deltoid region may also be used. Injection sites
should always be rotated within the
same region in order to reduce the risk of
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bahasa Melayu 31-07-2021

Cari amaran yang berkaitan dengan produk ini